BioAlliance Pharma: BioAlliance Pharma and Topotarget's new merged company Onxeo makes 1sthalf 2014 operating loss

Orphan oncology drug specialist Onxeo created by a merger between French company BioAlliance Pharma and Danish biopharmaceutical company Topotarget has made an operating loss in the first half of 2014 but are laying the foundations for the new company.